M. Patnaik

Publications565
h-index41
Citations7,451
Highly Influential Citations369
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Tefferi
  • 1,545 Publications • 73,719 Citations
  • H. Kantarjian
  • 2,737 Publications • 116,540 Citations
  • A. Pardanani
  • 597 Publications • 24,780 Citations
  • N. Gangat
  • 331 Publications • 6,559 Citations
  • Publications
  • Influence
Anthracycline dose intensification in acute myeloid leukemia.
  • 506
  • 29
Inherited antithrombin deficiency: a review
  • M. Patnaik, S. Moll
  • Medicine
  • Haemophilia : the official journal of the World…
  • 1 November 2008
Summary.  Antithrombin (AT) is a potent inactivator of thrombin and factor Xa and the major inhibitor of blood coagulation. Inherited AT deficiencies are uncommon, with prevalences in the general… Expand
  • 260
  • 27
  • PDF
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Clinical phenotype in systemic mastocytosis (SM) is markedly variable, which complicates prognostication and decision making regarding the choice and timing of therapy. In a retrospective study of… Expand
  • 283
  • 19
Eosinophilia: secondary, clonal and idiopathic
Blood eosinophilia signifies either a cytokine‐mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological neoplasm (primary). Secondary eosinophilia is usually… Expand
  • 245
  • 14
  • PDF
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
BACKGROUND Current drugs for myeloproliferative neoplasm-associated myelofibrosis, including Janus kinase (JAK) inhibitors, do not induce complete or partial remissions. Imetelstat is a 13-mer… Expand
  • 204
  • 13
  • PDF
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited by the associated toxicities. These include cytokine release syndrome… Expand
  • 143
  • 11
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a… Expand
  • 134
  • 10
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
SRSF2, SF3B1, and U2AF35 (U2AF1) are the three most frequent genes involved with spliceosome mutations in myeloid malignancies. SF3B1 mutations are most frequent (~80%) in myelodysplastic syndromes… Expand
  • 114
  • 9
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.
Among spliceosome component mutations, those involving SF3B1 are most frequent in myelodysplastic syndromes with ring sideroblasts (MDS-RS; ∼ 75% incidence) and SRSF2 in chronic myelomonocytic… Expand
  • 140
  • 8
Myelodysplastic syndromes: Contemporary review and how we treat
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. Diagnosis is currently based on the presence of… Expand
  • 116
  • 7
...
1
2
3
4
5
...